The US Food and Drug Administration (FDA) issued an alert today that cited preliminary evidence for a "substantial risk" for severe and symptomatic hypocalcemia and serious outcomes related to ...

The FDA said it's looking into the risk of severe hypocalcemia among patients on dialysis receiving denosumab (Prolia), citing the potential for severe outcomes, including hospitalization and death.

Patients at risk for postoperative hypocalcemia need more vigilant postoperative monitoring. Low preoperative serum calcium levels increase the likelihood of hypocalcemia after parathyroidectomy (PTx) ...

Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States Denosumab is widely used in the treatment of bone metastases ...

Please provide your email address to receive an email when new articles are posted on . The FDA issued a boxed warning stating denosumab increases severe hypocalcemia risk for adults with advanced CKD ...